Immunosuppression and renal outcome in congenital and pediatric steroid-resistant nephrotic syndrome.
Standard
Immunosuppression and renal outcome in congenital and pediatric steroid-resistant nephrotic syndrome. / Büscher, Anja K; Kranz, Birgitta; Büscher, Rainer; Hildebrandt, Friedhelm; Dworniczak, Bernd; Pennekamp, Petra; Kuwertz-Bröking, Eberhard; Wingen, Anne-Margret; John, Ulrike; Kemper, Markus J.; Monnens, Leo; Hoyer, Peter F; Weber, Stefanie; Konrad, Martin.
in: CLIN J AM SOC NEPHRO, Jahrgang 5, Nr. 11, 11, 2010, S. 2075-2084.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Immunosuppression and renal outcome in congenital and pediatric steroid-resistant nephrotic syndrome.
AU - Büscher, Anja K
AU - Kranz, Birgitta
AU - Büscher, Rainer
AU - Hildebrandt, Friedhelm
AU - Dworniczak, Bernd
AU - Pennekamp, Petra
AU - Kuwertz-Bröking, Eberhard
AU - Wingen, Anne-Margret
AU - John, Ulrike
AU - Kemper, Markus J.
AU - Monnens, Leo
AU - Hoyer, Peter F
AU - Weber, Stefanie
AU - Konrad, Martin
PY - 2010
Y1 - 2010
N2 - Mutations in podocyte genes are associated with steroid-resistant nephrotic syndrome (SRNS), mostly affecting younger age groups. To date, it is unclear whether these patients benefit from intensified immunosuppression with cyclosporine A (CsA). The aim of this study was to evaluate the influence of podocyte gene defects in congenital nephrotic syndrome (CNS) and pediatric SRNS on the efficacy of CsA therapy and preservation of renal function. Design, settings, participants, ; measurements: Genotyping was performed in 91 CNS/SRNS patients, irrespective of age at manifestation or response to CsA.
AB - Mutations in podocyte genes are associated with steroid-resistant nephrotic syndrome (SRNS), mostly affecting younger age groups. To date, it is unclear whether these patients benefit from intensified immunosuppression with cyclosporine A (CsA). The aim of this study was to evaluate the influence of podocyte gene defects in congenital nephrotic syndrome (CNS) and pediatric SRNS on the efficacy of CsA therapy and preservation of renal function. Design, settings, participants, ; measurements: Genotyping was performed in 91 CNS/SRNS patients, irrespective of age at manifestation or response to CsA.
M3 - SCORING: Zeitschriftenaufsatz
VL - 5
SP - 2075
EP - 2084
JO - CLIN J AM SOC NEPHRO
JF - CLIN J AM SOC NEPHRO
SN - 1555-9041
IS - 11
M1 - 11
ER -